Disc Medicine Q2 net loss widens to $59.53 million; R&D expenses rise to $46.93 million

Reuters2026/07/30 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Disc Medicine posted a wider Q2 net loss of USD 59.53 million, compared with a loss of USD 55.25 million a year earlier.
RD spending rose to USD 46.93 million from USD 46.32 million, due to advancing selcodebart and DISC-3405 studies, manufacturing, and higher headcount.
SGA expenses climbed to USD 18.14 million from USD 15.09 million on increased headcount.
Cash, cash equivalents and marketable securities fell to USD 717.75 million at June 30, 2026, from USD 791.15 million at end-2025; runway projected into 2029.
Bitopertin Phase 3 APOLLO topline data remains due in Q4 2026, with an FDA decision on a CRL response targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800763) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Disc Medicine Q2 net loss widens to $59.53 million; R&D expenses rise to $46.93 million

You may also like

Crypto prices